clinical trial results

Rosen Law Firm sues Aldeyra Therapeutics for false reproxalap trial claims. Lead plaintiff deadline: May 29, 2026.

Class action filed against $ALDYA alleging false statements about reproxalap trial results. Eligible investors covered Nov 2023-Mar 2026.

Rosen Law Firm files class action against $ALDX over allegedly misleading reproxalap clinical trial statements. Lead plaintiff deadline: May 29, 2026.

Class action filed against Aldeyra Therapeutics alleging false reproxalap trial data claims; investors from Nov 2023-Mar 2026 may be eligible.

Johnson Fistel investigates Viridian Therapeutics for potential securities law violations related to Phase 3 REVEAL-1 trial disclosures, offering shareholders potential loss recovery options.

$BIOG rallies as FDA approves high-dose Spinraza for spinal muscular atrophy, while litifilimab shows positive Phase 2 lupus results.

$BSX shares dropped 9.02% to 52-week lows despite positive WATCHMAN FLX and EKOS trial results, signaling investor caution amid broader growth concerns.

Novartis' Fabhalta slowed kidney function decline by 49.3% in Phase III trial, with FDA priority review granted for IgA nephropathy treatment.

Priovant's brepocitinib met Phase 3 endpoints for dermatomyositis treatment, earning FDA Priority Review with Q3 2026 decision expected.

Biogen announces second positive Phase 2 trial of litifilimab for cutaneous lupus, showing 11.8% greater disease reduction than placebo, advancing toward potential first targeted CLE therapy in 70 years.

Summit Therapeutics faces FDA decision on ivonescimab by November 2026 amid efficacy concerns, while Axsome and Madrigal positioned for outperformance.

Aclaris Therapeutics will present previously unreported Phase 2a trial results for ATI-2138, an oral dual ITK/JAK3 inhibitor, at the 2026 AAD Annual Meeting in Denver.

Eli Lilly's Ebglyss shows strong efficacy in pediatric atopic dermatitis trial, with 63% achieving significant skin clearance. Company plans regulatory submission for label update.

Four companies face April 6, 2026 lead plaintiff deadline in shareholder lawsuits alleging disclosure violations involving valuations, clinical trials, and fraudulent promotion.

PMV Pharmaceuticals reports 50% response rate for ovarian cancer drug rezatapopt, but faces funding pressure with cash runway extending only to Q2 2027.

Roche's obesity drug petrelintide achieved 10.7% weight loss in Phase 2 trials but significantly trails GLP-1 rivals Novo Nordisk and Eli Lilly, triggering sharp stock declines.

DBV Technologies announced strong Phase 3 data for VIASKIN® Peanut patch, with 82.8% of treated children showing improved tolerance. FDA submission planned for H1 2026.

Bristol Myers Squibb's experimental breast cancer drug showed survival improvements in advanced patients, though stock declined slightly following the announcement.

argenx's VYVGART met its primary endpoint in a Phase 3 ocular myasthenia gravis trial, showing significant symptom improvements. The company plans FDA approval for label expansion.

Fulcrum's pociredir shows strong fetal hemoglobin gains in sickle cell Phase 1b trial, with 58% of patients reaching therapeutic levels and reduced pain crises.